Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 1;69(13):5383-91.
doi: 10.1158/0008-5472.CAN-08-3845. Epub 2009 Jun 23.

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

Isabelle Ray-Coquard  1 , Claire Cropet, Martine Van Glabbeke, Catherine Sebban, Axel Le Cesne, Ian Judson, Olivier Tredan, Jaap Verweij, Pierre Biron, Inthidar Labidi, Jean-Paul Guastalla, Thomas Bachelot, David Perol, Sylvie Chabaud, Pancras C W Hogendoorn, Philippe Cassier, Armelle Dufresne, Jean-Yves Blay; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Affiliations

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

Isabelle Ray-Coquard et al. Cancer Res. .

Abstract

Lymphopenia is frequent in advanced cancers and predicts the toxicity of chemotherapy. Its effect on relapse and survival is uncertain. Its prognostic value for survival was analyzed in three databases of previously reported prospective multicenter studies: (a) FEC chemotherapy in metastatic breast carcinoma; (b) CYVADIC in advanced soft tissue sarcoma (European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group 62791); and (c) prospective, consecutive phase III studies of aggressive diffuse large-cell non-Hodgkin's lymphomas conducted at Centre Léon Bérard between 1987 and 1993. Univariate and multivariate analyses of prognostic factors for survival were performed. The incidence of lymphopenia of <1,000/microL before treatment was constant among the series: 25%, 24%, and 27%, respectively. Lymphopenia was significantly more frequent (P < 0.05) in metastatic breast cancer patients with performance status (PS) of >1, non-Hodgkin's lymphoma patients with international prognostic index (IPI) of > 0, and advanced soft tissue sarcoma and metastatic breast cancer patients with bone metastases. Inunivariate analysis, lymphopenia of <1,000/microL significantly correlated to overall survival in patients with metastatic breast cancer (median, 10 versus 14 mo; P < 0.0001), advanced soft tissue sarcoma (median, 5 versus 10 months; P < 0.01), and non-Hodgkin lymphoma (median, 11 versus 94 months; P < 0.0001). In multivariate analysis (Cox model), lymphopenia was an independent prognostic factor for overall survival in metastatic breast cancer [RR (relative risk), 1.8; 95% CI (confidence interval), 1.3-2.4] along with liver metastases and PS; in advanced soft tissue sarcoma (RR, 1.46; 95% CI, 1.0-2.1) along with liver metastases, lung metastases, and PS; and in non-Hodgkin's lymphoma (RR, 1.48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall (A) and progression-free (B) survival of non-Hodgkin’s lymphoma patients according to baseline lymphocyte counts
Figure 2
Figure 2
Overall (A) and progression-free survival (B) of hormone-resistant metastatic breast cancer patients according to baseline lymphocyte counts
Figure 3
Figure 3
Overall (A) and progression-free survival (B) of advanced soft tissue sarcoma patients according to baseline lymphocyte counts
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hortobagyi GN, Kris MG. Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers. Semin Oncol. 2002;29:1–3. - PubMed
    1. Crown J, Dieras V, Kaufmann M, et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol. 2002;3:719–27. - PubMed
    1. van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17:150–7. - PubMed
    1. Blay JY, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003;39:64–9. - PubMed
    1. Coiffier B. Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin Hematol. 2006;43:213–20. - PubMed

Publication types

MeSH terms

Substances